Bank of New York Mellon
ALXN

Bank of New York Mellon’s Alexion Pharmaceuticals ALXN Stock Holding History

Bank of New York Mellon’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,826,157
Closed -$335M – 4602
2021
Q2 		$335M Buy
1,826,157
+12,491
+0.7% +$2.14M 0.06% 269
2021
Q1 		$277M Sell
1,813,666
-105,311
-5% -$16.3M 0.06% 294
2020
Q4 		$300M Buy
1,918,977
+145,961
+8% +$18.8M 0.07% 263
2020
Q3 		$203M Buy
1,773,016
+93,861
+6% +$10.1M 0.05% 330
2020
Q2 		$188M Buy
1,679,155
+18,099
+1% +$1.92M 0.05% 327
2020
Q1 		$149M Buy
1,661,056
+4,838
+0.3% +$475K 0.05% 334
2019
Q4 		$179M Sell
1,656,218
-7,588
-0.5% -$812K 0.05% 359
2019
Q3 		$163M Buy
1,663,806
+39,854
+2% +$4.49M 0.04% 372
2019
Q2 		$213M Sell
1,623,952
-10,439
-0.6% -$1.35M 0.06% 304
2019
Q1 		$221M Sell
1,634,391
-429,179
-21% -$53.4M 0.06% 296
2018
Q4 		$201M Sell
2,063,570
-583,742
-22% -$69M 0.06% 282
2018
Q3 		$368M Sell
2,647,312
-374,644
-12% -$47M 0.09% 202
2018
Q2 		$375M Sell
3,021,956
-29,688
-1% -$3.47M 0.1% 195
2018
Q1 		$340M Sell
3,051,644
-61,088
-2% -$7.3M 0.09% 218
2017
Q4 		$372M Sell
3,112,732
-74,696
-2% -$9.1M 0.1% 206
2017
Q3 		$447M Sell
3,187,428
-162,393
-5% -$22.1M 0.12% 164
2017
Q2 		$408M Buy
3,349,821
+64,800
+2% +$7.54M 0.11% 179
2017
Q1 		$398M Buy
3,285,021
+392,742
+14% +$50.6M 0.11% 187
2016
Q4 		$354M Buy
2,892,279
+1,039,571
+56% +$127M 0.1% 211
2016
Q3 		$227M Sell
1,852,708
-6,776
-0.4% -$872K 0.07% 302
2016
Q2 		$217M Sell
1,859,484
-69,775
-4% -$9.9M 0.07% 308
2016
Q1 		$269M Sell
1,929,259
-552,912
-22% -$81.2M 0.08% 245
2015
Q4 		$473M Sell
2,482,171
-149,829
-6% -$26.2M 0.14% 145
2015
Q3 		$412M Sell
2,632,000
-25,531
-1% -$4.66M 0.13% 163
2015
Q2 		$481M Buy
2,657,531
+35,487
+1% +$6.12M 0.13% 156
2015
Q1 		$455M Sell
2,622,044
-184,863
-7% -$33.5M 0.12% 184
2014
Q4 		$520M Buy
2,806,907
+18,717
+0.7% +$3.47M 0.14% 160
2014
Q3 		$462M Sell
2,788,190
-5,038
-0.2% -$827K 0.13% 165
2014
Q2 		$436M Buy
2,793,228
+194,523
+7% +$30.7M 0.12% 176
2014
Q1 		$395M Sell
2,598,705
-7,366
-0.3% -$1.17M 0.11% 195
2013
Q4 		$346M Sell
2,606,071
-222,063
-8% -$26.6M 0.1% 215
2013
Q3 		$329M Sell
2,828,134
-48,246
-2% -$5.29M 0.1% 214
2013
Q2 		$265M Buy
+2,876,380
New +$277M 0.08% 243

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Bank of New York Mellon's ALXN Position: Q3 2021 in Review

Bank of New York Mellon sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,826,157 shares — an estimated $335M sold.

Bank of New York Mellon first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $520M in Q4 2014. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Bank of New York Mellon reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Bank of New York Mellon sold 1,826,157 Alexion Pharmaceuticals shares in Q3 2021, an estimated $335M.
  • Bank of New York Mellon first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Bank of New York Mellon's Alexion Pharmaceuticals position peaked at $520M in Q4 2014.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Bank of New York Mellon's 13F filing for Q3 2021, filed 12 Nov 2021.